GNFT Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	4 511.00
Średni wolumen	6 176.00
Kapitalizacja rynkowa	175.40M
EPS	$0 ( 2024-04-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.69
ATR14	$0 (0.00%)

Genfit SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genfit SA Finanse

Annual	2023
Przychody:	$28.57M
Zysk brutto:	$28.22M (98.81 %)
EPS:	$-0.580

FY	2023
Przychody:	$28.57M
Zysk brutto:	$28.22M (98.81 %)
EPS:	$-0.580

FY	2022
Przychody:	$20.20M
Zysk brutto:	$19.95M (98.77 %)
EPS:	$-0.480

FY	2021
Przychody:	$80.07M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$1.510

Financial Reports:

No articles found.

Genfit SA

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.